Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile3 entries
2023
Tacrolimus equivalence concerns
Valisure testing conducted for the American military reportedly found that an Intas-produced generic tacrolimus did not perform as an equivalent substitute for the reference product. The report also referenced earlier concerns involving an Accord tacrolimus product.
2022
Alleged laboratory data falsification at Sanand
A US FDA inspection reported alleged intentional manipulation of laboratory results and destruction of critical quality-control records at Intas's Sanand manufacturing facility.
2020
Indian price-control compliance notice
The National Pharmaceutical Pricing Authority issued a show-cause notice to Intas over an allegation that an anti-diabetic medicine had been sold without mandatory price approval.